TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Western Ontario and McMaster Universities Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Length of stay of the infant
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: radiographic union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma arginase activity and expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epinephrine Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants With a Mono-follicular Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants With At Least 1 Post Baseline Columbia-Suicide Severity Rating Scale (C-SSRS) Assessment (Suicide-Related Thoughts or Behaviours) Abnormality
Endpoint domain: Adverse events/effects
Primary endpoint: On-Trial Annualized Relapse Rate (ARR) as Determined by The Treating Physician
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Wound Hypertrophy Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to Oral Chemotherapy Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient Platelet Counts Post-transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Psychosocial measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of myocardial injury and myocardial infarction diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Supplemental Oxygen Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Child self-regulatory skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Child Prosocial Skills and Connections
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Child Cognitive Skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score in Cormack-Lehane scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Hospital Stay Duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Teachers' Intentions to Implement (ITI) at 3 Days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Teachers' Intervention Fidelity at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cyst freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of hepatitis B order panel
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Placement in Permanent Housing
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 2
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Clinical Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of total body weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: resolution or improvement of comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular Risk Factors Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of health care services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Without Greater Than Grade 3 GU/GI Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Antibiotic-induced disruption of breast milk microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic-induced disruption of infant stool microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composition of the intestinal microbiota and adverse health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients reaching individualized protein target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Patient Perception of Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Study Related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in Peripheral Blood Tregs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Summed Pain Intensity Difference Over the First 24 Hours (SPID24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total T-cell Level in Tumour Tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse Events (AE) Related to LTX-315 or Combination Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in sensory nerve conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Currently Employed
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Time to task completion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to Cessation of Vasopressor Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly Percentage of Heaving Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in CSF CXCL13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in CSF BAFF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients With NEC
Endpoint domain: Adverse events/effects
Primary endpoint: safety and tolerability of Multimeric-001 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parameters of cellular ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of nephrectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Genomic mutations comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from tobacco consumption abstinence at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of automated audiometry application
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MTD at which fewer than one third of patients experience dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of all adverse events, clinically significant changes in vital signs, ECGs and clinical laboratory tests
Endpoint domain: Adverse events/effects
Primary endpoint: Appropriate allergy documentation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in the rate of oxidative metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in energy transduction from oxidative metabolism to stroke work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New-onset arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 7-day Point Prevalence Smoking Abstinence at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point Prevalence Smoking Abstinence at 26 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic improvement of schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identify and record LFP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anterior Chamber Cell Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change from baseline self-care adherence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in nipple pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nipple damage change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PET amyloid burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PET tau deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Gamma activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alzheimer's Disease Assessment Scale -Cog Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnostic performance of antenatal echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total urine output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: LN dissection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Who Fail to Maintain BMD
Endpoint domain: Adverse events/effects
Primary endpoint: Change of furcation grade level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initiation of acute dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: doubling of serum creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: DNA methylation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Patients Amendable to Curative Surgical Interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prolapse and Incontinence Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Body weight (and BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: complete and partial pathologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Drug Concentration in Skin Biopsy Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Fatty Acid Uptake Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial Compliance - Augmentation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in FMR Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay in hospital among survivors to discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time of exercise on treadmill test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photosensitivity Index Under Full Range of UVB/UVA Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Photosensitivity Index Under UVA Exposure Only
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effectiveness of nicotine acid in treatment of postprandial dyslipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of Subjects Engrafting by Day +30 After Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quick Inventory of Depressive Symptoms-Self Rating (SR) 16 Item
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration of VM1500A in plasma and RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical utility of intraoperative contrast ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Expanded Disability Status Scale (EDSS) Plus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective overall response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Juvenile Arthritis Disease Activity Score (JADAS-71)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Juvenile Idiopathic Arthritis (JIA) Disease Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Fever Attributable to Systemic Juvenile Idiopathic Arthritis (sJIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with 12 months post index procedure
Endpoint domain: Mortality/survival
Primary endpoint: change in plasma glucose AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of gastric fistula development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Receiving Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of Inspired Oxygen (FiO2)/Partial Arterial Oxygen Pressure (PO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to Hospital Discharge With mRS ≤ 3
Endpoint domain: Mortality/survival
Primary endpoint: Scores on perceived risk scale after the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Scores on motivation to change behavior scale after the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gas passing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tic severity total subscore on the Yale Global Tic Severity Scale (YGTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who died after initiation of third-line therapy
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients who progressed to AP/BC after initiation of third-line therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients developed graft versus host disease after undergoing HSCT
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Blurred Vision After Instillation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Bitter Taste
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical improvement in cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: clinical improvement in hemoptysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postpartum pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed postpartum pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients admitted for diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of prepatent period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitemia and kinetics of parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of signs or symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions (SADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Ki67 expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: YMRS total score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with any adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cocaine Craving Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: visual analogue pain scale - resting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analogue pain scale - moving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life after delivery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Area Under the Curve From Time Zero to Infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Solicited Injection Site Reactions and Systemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Japanese Encephalitis Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Japanese Encephalitis Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time weighted sum of pain intensity difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of solifenacin succinate in reducing OAB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Daily Peripheral Neuropathy Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of rise of hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Treated Lobar Volume Reduction (TLVR) responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-year outcome of laparoscopic gastric sleeve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hepatitis B virus infection
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of Death, non-fatal myocardial infarction or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in FFR from baseline to follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in lipid core burden index at the 4mm maximal segment (MaxLCBI4mm) from baseline to follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage change in PPPASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with technical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of subjects with and without microbleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of participants with symptoms at presentation to the research clinic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chalder's Fatigue Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Amount of drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Affective stability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage Change in Exercise Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Alanine Aminotransferase (ALT) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Anti-CMV T cellular immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients who have established the diagnosis of SAHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in the therapeutic decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving radiotherapy as anti-cancer treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients receiving surgery as anti-cancer treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients receiving chemotherapy as anti-cancer treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients receiving targeted therapy as anti-cancer treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients receiving supportive care as anti-cancer treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Distribution of Treatment History in Head and Neck Cancer (HNC) patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use